G. R. Imametdinova
G. R. Imametdinova has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
1 shared publication - Elizaveta A. Novokhatskaya
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per. 10, Bld. 3, 101000 Moscow, Russia
1 shared publication I. V. Kuznetsova
National Medical Research Center for Therapy and Preventive Medicine
1 shared publication- N. V. Chichasova
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
1 shared publication T. A. Ryabinina
National Medical Research Center for Therapy and Preventive Medicine
1 shared publication
Latest Publications
- Open Access
- 16 June 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (7S) , 3641
"Ruling out all the wrong, we get to the truth". Case report
Polymyalgia rheumatica is a systemic inflammatory disease that is rarely diagnosed in clinical practice due to the low awareness of physicians and the absence of specific diagnostic markers. The case report is of particular interest due to the absence of typical laboratory signs and the presence of concomitant diseases in the patient with similar clinical manifestations. Timely diagnosis and the appointment of adequate therapy made it possible to achieve clinical and laboratory remission without irreversible consequences for the patient’s health.
- 16 June 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (7S) , 3641
Open Access"Ruling out all the wrong, we get to the truth". Case report
Polymyalgia rheumatica is a systemic inflammatory disease that is rarely diagnosed in clinical practice due to the low awareness of physicians and the absence of specific diagnostic markers. The case report is of particular interest due to the absence of typical laboratory signs and the presence of concomitant diseases in the patient with similar clinical manifestations. Timely diagnosis and the appointment of adequate therapy made it possible to achieve clinical and laboratory remission without irreversible consequences for the patient’s health.
- Open Access
- 16 July 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 128-134
Safe therapy of osteoarthritis: place of topical nonsteroidal anti-inflammatory drugs
The article discusses the social significance of osteoarthritis as a widespread disease that develops mainly in older people, which makes it difficult to carry out anti-inflammatory and analgesic therapy due to the frequent combination of osteoarthritis with other diseases at this age, the need to treat comorbid conditions, which is often poorly combined with systemic therapy with non-steroidal anti-inflammatory drugs. It is noted that osteoarthritis not only worsens the quality of life of patients, but also leads to a decrease in the length of their life, which emphasizes the medical and social importance of conducting the safest possible therapy for this disease. Data on the negative impact of the presence of chronic pain on the progression of osteoarthritis are presented. The negative aspects of the use of oral forms of non-steroidal anti-inflammatory drugs are discussed: the development of adverse events primarily from the gastrointestinal tract and cardiovascular system, the negative effect on the synthesis of glycoaminoglycans («chondronegative effect»). Discusses the place of topical forms of NSAIDs in the treatment of patients with osteoarthritis in accordance with the recommendations of the International society for the use of topical forms of NSAIDs in the management of patients with osteoarthritis of large and small joints. Data on transdermal transport of the topical form of diclofenac, a small molecule with lipophilic properties, are presented. Data on the effectiveness of topical forms of diclofenac in comparison with oral forms are presented according to numerous randomized controlled trials, and the comparable effectiveness of both forms of diclofenac is demonstrated, with maximum safety of the topical form. A special structure of Voltaren® Emulgel (Voltaren® Emulgel), combining the properties of a gel and cream, which provides rapid transdermal penetration and longer retention of the active substance in the area of inflammation, is described, as well as a special prolonged form of Voltaren® Emulgel), which creates additional convenience for use.
- 16 July 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 128-134
Open AccessSafe therapy of osteoarthritis: place of topical nonsteroidal anti-inflammatory drugs
The article discusses the social significance of osteoarthritis as a widespread disease that develops mainly in older people, which makes it difficult to carry out anti-inflammatory and analgesic therapy due to the frequent combination of osteoarthritis with other diseases at this age, the need to treat comorbid conditions, which is often poorly combined with systemic therapy with non-steroidal anti-inflammatory drugs. It is noted that osteoarthritis not only worsens the quality of life of patients, but also leads to a decrease in the length of their life, which emphasizes the medical and social importance of conducting the safest possible therapy for this disease. Data on the negative impact of the presence of chronic pain on the progression of osteoarthritis are presented. The negative aspects of the use of oral forms of non-steroidal anti-inflammatory drugs are discussed: the development of adverse events primarily from the gastrointestinal tract and cardiovascular system, the negative effect on the synthesis of glycoaminoglycans («chondronegative effect»). Discusses the place of topical forms of NSAIDs in the treatment of patients with osteoarthritis in accordance with the recommendations of the International society for the use of topical forms of NSAIDs in the management of patients with osteoarthritis of large and small joints. Data on transdermal transport of the topical form of diclofenac, a small molecule with lipophilic properties, are presented. Data on the effectiveness of topical forms of diclofenac in comparison with oral forms are presented according to numerous randomized controlled trials, and the comparable effectiveness of both forms of diclofenac is demonstrated, with maximum safety of the topical form. A special structure of Voltaren® Emulgel (Voltaren® Emulgel), combining the properties of a gel and cream, which provides rapid transdermal penetration and longer retention of the active substance in the area of inflammation, is described, as well as a special prolonged form of Voltaren® Emulgel), which creates additional convenience for use.